After years of development, an experimental anti-fentanyl vaccine developed by ARMR Sciences and the University of Houston has entered early-stage human trials. According to the press release by ARMR Sciences, the vaccine could become an additional tool to help reduce overdose deaths if it proves safe and effective. Specifically, earlier in June, ARMR Sciences announced that its experimental anti-fentanyl vaccine generated an immune response against fentanyl in humans while demonstrating a favourable safety profile. The findings mark a key milestone toward determining whether the immune response can ultimately protect against fentanyl.
ARMR-100 is an experimental vaccine designed to stimulate the production of anti-fentanyl antibodies that bind to fentanyl in the bloodstream, preventing it from reaching the brain and potentially reducing the risk of overdose. Currently in a Phase 1/2 clinical trial, the vaccine is intended to provide protection for six to 12 months, with efficacy testing against fentanyl expected to begin in the third quarter of 2026.
“The antibody response we observed at the lowest dose level tested has been robust, with anti-fentanyl IgG titers well above pre-vaccination baseline. These early immunogenicity data are encouraging as we advance to higher dose cohorts and, ultimately, to the human fentanyl challenge phase of the study,” said Dr. Seth Toback, Chief Medical Officer of ARMR Sciences in a press release.
Data released by the Center for Disease Control and Prevention (CDC) shows that fentanyl is responsible for over 100 deaths per day in the U.S., with illicit drug overdose becoming the leading cause of death for Americans aged 18-45 years. Moreover, over the past decade, fentanyl was linked to over 450,000 deaths in the U.S.
“We are turning what many called impossible into reality,” said Collin Gage, CEO of ARMR Sciences in a press release. “These positive early results are a testament to the deeply experienced team of scientists, researchers, and medical professionals we have assembled. While there is still important work ahead, we believe today’s milestone further validates our approach and reinforces our confidence in the path forward as we continue advancing a potential solution that could save countless lives.”
According to the press release from ARMR, the vaccine has been well tolerated in the first 24 participants across the cohorts, with no serious adverse events reported and only mild, short-lived side effects such as occasional headaches. The trial’s Safety Committee has repeatedly cleared the study to progress to higher dose levels based on the favourable safety profile. At the lowest dose tested, ARMR-100 generated a meaningful anti-fentanyl antibody response, supporting advancement to the next phase, which will evaluate its ability to protect against fentanyl exposure in humans.
